This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read PAVmed’s 8K filing here.
PAVmed Company Profile
PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
See Also
- Five stocks we like better than PAVmed
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Consumer Discretionary Stocks Explained
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Insider Trades May Not Tell You What You Think
- Despite Short-Term Risks Freeport McMoran Worth a Look
